GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3B) » Definitions » Cash, Cash Equivalents, Marketable Securities

EyePoint Pharmaceuticals (FRA:PV3B) Cash, Cash Equivalents, Marketable Securities : €275.40 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

EyePoint Pharmaceuticals's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 (€127.44 Mil) to Dec. 2023 (€303.57 Mil) but then stayed the same from Dec. 2023 (€303.57 Mil) to Mar. 2024 (€275.40 Mil).

EyePoint Pharmaceuticals's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€187.23 Mil) to Dec. 2022 (€136.47 Mil) but then increased from Dec. 2022 (€136.47 Mil) to Dec. 2023 (€303.57 Mil).


EyePoint Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for EyePoint Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.99 36.92 187.23 136.47 303.57

EyePoint Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 114.40 131.56 127.44 303.57 275.40

EyePoint Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


EyePoint Pharmaceuticals  (FRA:PV3B) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


EyePoint Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (FRA:PV3B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3B) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (FRA:PV3B) Headlines

No Headlines